Integral Molecular aids with safety testing of COVID-19 antibodies

By The Science Advisory Board staff writers

June 12, 2020 -- Integral Molecular is applying its membrane proteome array (MPA) technology for antibody specificity profiling to accelerate development of SARS-CoV-2 therapeutic antibodies.

In collaboration with Abound Bio, the MPA technology has been used to identify a monoclonal antibody that targets and neutralizes SARS-CoV-2. The antibody did not display any off-target binding on the MPA and has been selected for further development.

Nearly 25% of preclinical antibodies have off-target binding to unintended protein targets, which can lead to adverse effects in patients. The company's MPA provides specificity results in less than a month, which is faster than other traditional preclinical safety experiments, according to the company.

The MPA is a collection of 6,000 membrane proteins expressed in live cells, representing nearly the entire human membrane proteome. Integral has also launched an antibody neutralization test using pseudotyped SARS-CoV-2 reporter viruses.

Integral Molecular wins COVID-19 NIAID award
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded Integral Molecular $1 million to help discover vaccines and therapeutics...

Copyright © 2020

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter